CN101415697A - 制备非晶的、无水结晶的或水合结晶的多西紫杉醇的方法 - Google Patents
制备非晶的、无水结晶的或水合结晶的多西紫杉醇的方法 Download PDFInfo
- Publication number
- CN101415697A CN101415697A CNA2006800517030A CN200680051703A CN101415697A CN 101415697 A CN101415697 A CN 101415697A CN A2006800517030 A CNA2006800517030 A CN A2006800517030A CN 200680051703 A CN200680051703 A CN 200680051703A CN 101415697 A CN101415697 A CN 101415697A
- Authority
- CN
- China
- Prior art keywords
- docetaxel
- solvent
- crystalline hydrate
- preparing
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 215
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 214
- 238000000034 method Methods 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title abstract description 26
- 238000001556 precipitation Methods 0.000 claims abstract description 44
- 239000002904 solvent Substances 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 49
- 239000003960 organic solvent Substances 0.000 claims description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 239000013078 crystal Substances 0.000 claims description 25
- 239000012046 mixed solvent Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000012454 non-polar solvent Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 150000004684 trihydrates Chemical class 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- 150000004683 dihydrates Chemical class 0.000 claims description 6
- 150000004682 monohydrates Chemical class 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 230000003139 buffering effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 150000001983 dialkylethers Chemical group 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 22
- 238000002425 crystallisation Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- 238000000634 powder X-ray diffraction Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 238000000151 deposition Methods 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- XCDIRYDKECHIPE-QHEQPUDQSA-N docetaxel trihydrate Chemical compound O.O.O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 XCDIRYDKECHIPE-QHEQPUDQSA-N 0.000 description 3
- 229950010692 docetaxel trihydrate Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
测量仪器 | Rigaku,D/MAX 3B,XRPD |
测量方法 | 将大约20mg的样品固定于XRPD取样器中,从5℃至25℃扫描若干分钟 |
X射线源 | CuKa 40kV,40mA |
仪器 | Hewlett Packard 1100 HPLC |
柱 | Curosil PFP 4.6X50,5微米 |
柱温 | 35℃ |
移动相 | 乙腈:水(35-65%浓度梯度) |
流动速率 | 1ml/min |
注入量 | 10ul |
探测器 | UV(227nm) |
Claims (13)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060000276A KR100995390B1 (ko) | 2006-01-02 | 2006-01-02 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
KR1020060000276 | 2006-01-02 | ||
KR10-2006-0000276 | 2006-01-02 | ||
PCT/KR2006/004539 WO2007078050A2 (en) | 2006-01-02 | 2006-11-02 | Method for preparation of amorphous, anhydrous crystalline, or hydrated crystalline docetaxel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101415697A true CN101415697A (zh) | 2009-04-22 |
CN101415697B CN101415697B (zh) | 2012-10-17 |
Family
ID=38228618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800517030A Active CN101415697B (zh) | 2006-01-02 | 2006-11-02 | 制备非晶的多西紫杉醇的方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8163940B2 (zh) |
EP (1) | EP1973894B1 (zh) |
JP (1) | JP5149810B2 (zh) |
KR (1) | KR100995390B1 (zh) |
CN (1) | CN101415697B (zh) |
BR (1) | BRPI0620850A2 (zh) |
ES (1) | ES2576635T3 (zh) |
WO (1) | WO2007078050A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103601704A (zh) * | 2013-11-22 | 2014-02-26 | 赵军旭 | 无定形卡巴他赛的制备 |
CN103764637A (zh) * | 2011-04-12 | 2014-04-30 | 普拉斯化学品有限公司 | 卡巴他赛的固态形式及其制备方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435249B2 (en) * | 1997-11-12 | 2008-10-14 | Covidien Ag | Electrosurgical instruments which reduces collateral damage to adjacent tissue |
NZ576355A (en) * | 2006-10-20 | 2012-04-27 | Scinopharm Singapore Pte Ltd | Process for making crystalline anhydrous docetaxel |
WO2008102374A1 (en) * | 2007-02-20 | 2008-08-28 | Dabur Pharma Limited | Amorphous form of docetaxel |
KR100878455B1 (ko) * | 2007-04-10 | 2009-01-13 | 한미약품 주식회사 | 안정한 무수결정형 도세탁셀 및 이의 제조방법 |
US20100197944A1 (en) * | 2007-07-04 | 2010-08-05 | Dr. Reddy's Laboratories Limited | Docetaxel process and polymorphs |
EP2080764B1 (en) * | 2008-01-18 | 2012-08-22 | INDENA S.p.A. | Solid forms of ortataxel |
KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
KR101068230B1 (ko) * | 2009-03-03 | 2011-09-28 | 정규능 | 도세탁셀의 제조방법, 그 중간체 및 이의 제조방법 |
WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
BRPI1014854A2 (pt) * | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
ES2621613T3 (es) * | 2009-11-04 | 2017-07-04 | Emcure Pharmaceuticals Limited | Un proceso mejorado para la preparación de derivados de taxano |
KR101149600B1 (ko) * | 2009-12-31 | 2012-05-29 | 주식회사 삼양제넥스바이오 | 고순도 무수결정형 도세탁셀 제조방법 |
CN102970990A (zh) | 2010-05-03 | 2013-03-13 | 帝国制药美国公司 | 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法 |
WO2012160568A1 (en) * | 2011-05-23 | 2012-11-29 | Shilpa Medicare Limited | Process for preparing docetaxel trihydrate polymorph |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9629629B2 (en) | 2013-03-14 | 2017-04-25 | Ethicon Endo-Surgey, LLC | Control systems for surgical instruments |
WO2015188045A1 (en) * | 2014-06-06 | 2015-12-10 | Abbvie Inc. | Crystal forms |
CN111039984B (zh) * | 2018-10-15 | 2022-06-07 | 上海盟科药业股份有限公司 | 康泰唑胺酯的药物晶体及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722191B1 (fr) | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
KR100290635B1 (ko) | 1998-12-23 | 2001-06-01 | 박종헌 | 무정형 팩리택셀의 제조방법 |
US6881852B2 (en) * | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
US6838569B2 (en) | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
CN1268619C (zh) | 2003-05-08 | 2006-08-09 | 上海迪赛诺化学制药有限公司 | 多烯紫杉醇三水化合物的制备方法 |
ES2325506T3 (es) | 2003-12-12 | 2009-09-07 | Quiral Quimica Do Brasil | Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones. |
CN100420681C (zh) * | 2005-04-29 | 2008-09-24 | 上海奥锐特国际贸易有限公司 | 多烯紫杉醇三水物的制备方法 |
US20070142457A1 (en) * | 2005-10-12 | 2007-06-21 | Alessandro Pontiroli | Crystalline forms of docetaxel and processes for their preparation |
-
2006
- 2006-01-02 KR KR1020060000276A patent/KR100995390B1/ko active IP Right Grant
- 2006-11-02 JP JP2008549408A patent/JP5149810B2/ja active Active
- 2006-11-02 WO PCT/KR2006/004539 patent/WO2007078050A2/en active Application Filing
- 2006-11-02 US US12/159,812 patent/US8163940B2/en active Active
- 2006-11-02 CN CN2006800517030A patent/CN101415697B/zh active Active
- 2006-11-02 ES ES06812378.5T patent/ES2576635T3/es active Active
- 2006-11-02 BR BRPI0620850-9A patent/BRPI0620850A2/pt not_active IP Right Cessation
- 2006-11-02 EP EP06812378.5A patent/EP1973894B1/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103764637A (zh) * | 2011-04-12 | 2014-04-30 | 普拉斯化学品有限公司 | 卡巴他赛的固态形式及其制备方法 |
CN103601704A (zh) * | 2013-11-22 | 2014-02-26 | 赵军旭 | 无定形卡巴他赛的制备 |
Also Published As
Publication number | Publication date |
---|---|
KR100995390B1 (ko) | 2010-11-19 |
WO2007078050A3 (en) | 2008-01-03 |
EP1973894A2 (en) | 2008-10-01 |
JP5149810B2 (ja) | 2013-02-20 |
WO2007078050A2 (en) | 2007-07-12 |
JP2009522351A (ja) | 2009-06-11 |
KR20070072786A (ko) | 2007-07-05 |
US8163940B2 (en) | 2012-04-24 |
ES2576635T3 (es) | 2016-07-08 |
CN101415697B (zh) | 2012-10-17 |
EP1973894B1 (en) | 2016-04-06 |
EP1973894A4 (en) | 2010-11-17 |
BRPI0620850A2 (pt) | 2013-01-29 |
US20090018353A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101415697B (zh) | 制备非晶的多西紫杉醇的方法 | |
EP3349762B1 (en) | Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof | |
US7507813B2 (en) | Amorphous cefuroxime axetil and preparation process therefore | |
KR101479389B1 (ko) | 아자시클로헥사펩타이드 또는 그 염의 정제방법 | |
JP6321735B2 (ja) | エルタペネムナトリウムの結晶形およびその調製方法 | |
CN104768935A (zh) | 恩杂鲁胺的多晶型形式及其制备 | |
CN107814802A (zh) | 一种制备枸橼酸托法替尼药用晶型的新方法 | |
CN103874692A (zh) | 卡巴他赛的无定形形式和用于其制备的方法 | |
CN111217372A (zh) | 手性介孔核-壳结构二氧化硅纳米粒及其制备方法和应用 | |
KR101596554B1 (ko) | 펩타이드계 물질의 결정체 및 그의 제조방법과 용도 | |
WO2008102374A1 (en) | Amorphous form of docetaxel | |
RU2482110C2 (ru) | Способ кристаллизации гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этил]-1,3-пропандиола | |
CN102351812A (zh) | 甲磺酸桂哌齐特晶型iii及其制备方法 | |
WO2015180680A1 (zh) | 一种环肽类化合物的结晶粉末及其制备方法和用途 | |
KR100965867B1 (ko) | 수화결정형 도세탁셀의 제조방법 | |
KR20120096200A (ko) | 결정형 도세탁셀 및 이의 제조방법 | |
CN101228110A (zh) | 3-[2-(二甲基氨基)甲基-(环己-1-基)]-苯酚马来酸盐及其结晶形式 | |
KR100965866B1 (ko) | 무수결정형 도세탁셀의 제조방법 | |
WO2011085130A1 (en) | Solid state forms of fosamprenavir calcium salt and process for preparation thereof | |
NZ581634A (en) | Direct dissolution of docetaxel in a solvent in polysorbate 80 | |
KR100965869B1 (ko) | 수화결정형 파클리탁셀의 제조방법 | |
Ab Rahman et al. | Effect of Solvents and Crystallization Methods on the Formation of Carbamazepine-Saccharin Co-Crystal | |
TW201714878A (zh) | 氘代咪唑酮化合物之晶型i及其製備方法和用途 | |
CN118255749A (zh) | 一种阿利沙坦酯微粉的制备方法 | |
WO2018209667A1 (zh) | 多环杂环化合物的晶型、其制备方法、应用及组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SAMYANG GENEX BIO CO., LTD. Free format text: FORMER OWNER: SAMYANG GENEX CORP. Effective date: 20120604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120604 Address after: Seoul, South Kerean Applicant after: Samyang Genex Corp. Address before: Seoul, South Kerean Applicant before: Samyang Genex Corp. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KYOWA MACHINERY CO., LTD. SAMYANG BIOLOGICAL PHARM Free format text: FORMER OWNER: SAMYANG GENEX BIO CO., LTD. Effective date: 20140317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140317 Address after: Seoul, South Kerean Patentee after: Casio Hitachi Mobile Comm Co. Patentee after: Miyaki biological pharmacy Address before: Seoul, South Kerean Patentee before: Samyang Genex Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210813 Address after: Seoul City, Korea Patentee after: Sanyang holding Co. Address before: Seoul, South Kerean Patentee before: SAMYANG BIOPHARMACEUTICALS Corp. |
|
TR01 | Transfer of patent right |